Photo credit: www.investing.com
Twist Bioscience Director Sells Shares Amid Strong Financial Performance
Robert Chess, a board member at Twist Bioscience Corporation (NASDAQ:TWST), has sold 5,000 shares of the company’s stock, as disclosed in a recent filing with the Securities and Exchange Commission. The shares were sold at a price of $50.00 each, resulting in a total value of $250,000. Notably, this price exceeds the current market price, which is approximately $43.60, signaling some volatility in the stock according to InvestingPro’s data. After this transaction, Chess retains direct ownership of 16,641 shares. Furthermore, the Chess 1997 Trust, which he and his spouse manage as sole trustees and beneficiaries, holds an additional 42,528 shares. The sale was conducted under a Rule 10b5-1 trading plan that Chess established in August 2024.
Twist Bioscience is currently valued at $2.6 billion and exhibits strong liquidity, as indicated by a current ratio of 4.88. A detailed analysis from InvestingPro sheds light on six additional critical factors concerning TWST’s financial status and growth opportunities, which are explored in their comprehensive Pro Research Report encompassing over 1,400 leading stocks.
In other developments, Twist Bioscience recently concluded its fiscal year 2024 on a high note, with Q4 revenues climbing 27% to $84.7 million. Overall, the company recorded a substantial annual revenue increase of 28%, totaling $330 million. Additionally, Twist surpassed its own gross margin expectations for the quarter, achieving 45.1%, while also reporting an increase in annual gross margin to 42.6%.
Analysts from Baird have reiterated their “Outperform” rating on Twist Bioscience, elevating the price target to $48.00. Similarly, TD Cowen has maintained its “Buy” rating, underscoring the company’s strong financial outlook for fiscal year 2025. Scotiabank has also raised its price target for the stock to $54, continuing their “Sector Outperform” rating.
Looking ahead, Twist Bioscience’s initial guidance for fiscal year 2025 anticipates revenue expansion of 17% to 20% year-over-year, primarily driven by advancements in the Next Generation Sequencing (NGS) and Synthetic Biology (SynBio) segments. The company aims to improve its adjusted EBITDA by approximately $30 million compared to the previous year, reflecting a positive trajectory in its financial health and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Source
www.investing.com